ZSTK-474

Research use only, not for human use.

A potent inhibitor of class I PI3K isoforms with IC50 of 17 nM, 53 nM, and 6 nM for p110β, p110γ, and p110δ, respectively.

A potent inhibitor of class I PI3K isoforms with IC50 of 17 nM, 53 nM, and 6 nM for p110β, p110γ, and p110δ, respectively; shows potent antiproliferative activity against a panel of 39 human cancer cell lines with mean GI50 of 0.32 uM, more effectively than that of LY294002 or wortmannin; induces apoptosis in OVCAR3 cells, and induces complete G1-phase arrest but not apoptosis in A549 cells at 10 uM; completely inhibits the growth of A549, PC-3, and WiDr xenografts in mice at 400mg/kg; and induces the regression of A549 xenograft tumors.Solid Tumors Phase 1 Clinical

ZSTK474;ZSTK 474

PI3K/Akt/mTOR signaling

PI3K

PI3K;PI3Kα;PI3Kβ;PI3Kγ;PI3Kδ

Cancer

Solid Tumors

475110-96-4

417.41

C19H21F2N7O2

>98% (HPLC)

10 mM in DMSO

FC(C1=NC2=CC=CC=C2N1C3=NC(N4CCOCC4)=NC(N5CCOCC5)=N3)F

1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-

(-20℃)

With Ice Pack

≥ 2 years